MyMD Pharmaceuticals Enrolls First Individual in Stage 2 Professional Test of MYMD-1 as a Therapy for Delaying Aging and also Extending Healthy Life-span

MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals Inc (” MyMD” or “the Company”), a professional phase pharmaceutical company dedicated to expanding healthy lifespan, today introduced that the first individual has been registered in the Company’s Phase 2 clinical trial of lead prospect MYMD-1, an oral immune regulator medication, as a treatment for delaying aging and expanding healthy lifespan.

The primary endpoint for the Stage 2 double-blind, placebo-controlled medical test is to accomplish a reduction in the flowing levels of (TNF-α), lump necrosis element receptor I (TNFRI) as well as IL-6. TNF-α and IL-6 are the healthy proteins in the body that trigger swelling as well as assist trigger the process of aging. The additional measures of the test will be the safety and security, tolerability, and also pharmacokinetics in this population of people.

” In a Phase 1 medical trial of MYMD-1, we demonstrated the drug’s statistically substantial efficiency in decreasing degrees of TNF-α, a key player in creating pathological aging, in the blood. The FDA has approved TNF-α reduction as the key endpoint for our Stage 2 research study, which our team believe settings us well for a successful Phase 2 result,” said Chris Chapman, M.D., President, Director and also Principal Medical Police Officer of MyMD. “The initiation of person registration in this research breakthroughs our mission to slow the aging procedure, stop loss of muscle mass cells in aging, restriction frailty, and also prolong healthy and balanced lifespan.”

MyMD has mentioned that there are no FDA-approved medications for dealing with aging conditions and extending healthy life-span people, a market expected to be at least $600 billion by 20251 according to a significant financial investment financial institution. TNF-α blockers are the most proposed drugs by profits, a worldwide market of around $40 billion per year,2 and, according to Nature Aging journal,3 a downturn in aging that would enhance life expectancy by one year is worth $38 trillion as well as by ten years is worth $367 trillion.

Along with aging, MYMD-1’s unique action in managing the immune system and also treating chronic inflammation is being established for the therapy of autoimmune disease, including rheumatoid joint inflammation (RA), several sclerosis (MS), diabetic issues, and inflammatory bowel illness.

” We intend to start writing procedures for a Stage 2 pilot study of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman noted. “The rising occurrence of rheumatoid arthritis as well as other autoimmune as well as inflammatory diseases are driving demand for TNF preventions like MYMD-1, as well as our team believe our by mouth administered drug with very low poisoning would certainly be turbulent to the $60 billion market for RA if accepted by the FDA for this sign.”

Rheumatoid arthritis influences approximately 40 million people around the world.4.

About MYMD-1.

Initially created for autoimmune conditions, MYMD-1’s key purpose is to slow down the aging procedure, prevent sarcopenia as well as frailty, as well as expand healthy and balanced lifespan. Because it can go across the blood-brain obstacle as well as gain access to the central nerves (CNS), MYMD-1 is also positioned to be a possible therapy for brain-related problems. Its mechanism of action and also efficacy in illness including several sclerosis (MS) and also thyroiditis have actually been studied through partnerships with several academic institutions. MYMD-1 is additionally showing guarantee in pre-clinical researches as a possible treatment for article- COVID-19 complications and as an anti-fibrotic and also anti-proliferation restorative.

MYMD-1 has actually shown performance in pre-clinical research studies in managing the body immune system by executing as a careful inhibitor of lump necrosis factor-alpha (TNF-α), a chauffeur of persistent inflammation. Unlike various other therapies, MYMD-1 has been shown in these pre-clinical studies to precisely obstruct TNF-α when it becomes overactivated in autoimmune diseases and also cytokine tornados, yet not obstruct it from doing its regular work of being a very first responder to any type of routine sort of moderate infection. MYMD-1’s ease of dental dosing is another differentiator compared to currently available TNF-α blockers, every one of which call for distribution by injection or mixture. No approved TNF inhibitor has actually ever before been dosed by mouth. On top of that, the drug is not immunosuppressive and also has not been revealed to create the severe adverse effects common with conventional therapies that deal with swelling.

Concerning MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical business devoted to extending healthy and balanced lifespan, is concentrated on creating 2 unique healing platforms that treat the sources of disease rather than just resolving the signs and symptoms. MYMD-1 is a drug platform based on a professional stage little particle that manages the body immune system to manage TNF-α, which drives chronic inflammation, and also other pro-inflammatory cell signaling cytokines. MYMD-1 is being created to postpone aging, increase longevity, and also treat autoimmune conditions and COVID-19- linked clinical depression. The Company’s 2nd medication platform, Supera-CBD, is being created to deal with chronic discomfort, addiction and epilepsy. Supera-CBD is a novel synthetic by-product of cannabidiol (CBD) and is being created to resolve and also improve upon the quickly growing CBD market, which includes both FDA approved medications and CBD items not currently controlled as drugs. For more information, check out